Saivan Kattoula, in Jamul, CA - Pharmacist

Saivan Kattoula, is a Pharmacist based in Jamul, California. Saivan Kattoula is licensed to practice in California (license number 84876) and his current practice location is 3560 Turnberry Dr, Jamul, California. He can be reached at his office (for appointments etc.) via phone at (619) 490-6567.

NPI number for Saivan Kattoula is 1265109854 and his current mailing address is 3560 Turnberry Dr, Jamul, California. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1265109854.

Contact Information

	Saivan Kattoula,
	3560 Turnberry Dr, Jamul, CA 91935-1651
	(619) 490-6567
	Not Available

Healthcare Provider's Profile

Full Name	Saivan Kattoula
Gender	Male
Speciality	Pharmacist
Location	3560 Turnberry Dr, Jamul, California
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1265109854
Provider Enumeration Date: 08/23/2021
Last Update Date: 08/23/2021

Medical Identifiers

Medical identifiers for Saivan Kattoula such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1265109854	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
183500000X	Pharmacist	84876 (California)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Saivan Kattoula is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Saivan Kattoula, 3560 Turnberry Dr, Jamul, CA 91935-1651 Ph: () -	Saivan Kattoula, 3560 Turnberry Dr, Jamul, CA 91935-1651 Ph: (619) 490-6567

News Archive

Enrollment complete in Idera's IMO-3100 Phase 2 trial for psoriasis

Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.

Kerr announces launch of new Nexus RMGI dental cement

Kerr Corporation, a leading manufacturer of innovative dental restorative materials, has announced the launch of its new Nexus RMGI, a unique dental cement that combines One-Peel™ cleanup, outstanding durability, and improved esthetic qualities for consistent, predictable outcomes.

PEPFAR committed to programs aimed at children to reach AIDS-free generation

Citing data on how HIV/AIDS has affected children worldwide, whether directly or through the death of one or both parents, U.S. Global AIDS Coordinator Ambassador Eric Goosby, who also heads the State Department's Office of Global Health Diplomacy, writes in the agency's "DipNote" blog that children are vulnerable "to the social, emotional, economic, and environmental effects that HIV and AIDS has on families, communities, and countries."

IBM and OhioHealth collaborate to aid in prevention of infections in hospitals

OhioHealth and IBM today announced a collaboration to aid in the prevention of infections using a first-of-a-kind network of wireless sensors and real-time Big Data analytics that measure hand-washing practices.

Saivan Kattoula, - Pharmacist in Jamul, CA